Post-PCI bivalirudin infusion , as compared with no infusion , did not significantly decrease the rate of urgent target-vessel revascularization , definite stent thrombosis , or net adverse clinical events ( @ % and @ % , respectively ; relative risk , @ ; @ % CI , @ to @ ; P = @ ) .